0001415889-24-014646.txt : 20240528
0001415889-24-014646.hdr.sgml : 20240528
20240528161012
ACCESSION NUMBER: 0001415889-24-014646
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240523
FILED AS OF DATE: 20240528
DATE AS OF CHANGE: 20240528
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Resnick Joshua
CENTRAL INDEX KEY: 0001690959
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39979
FILM NUMBER: 24991869
MAIL ADDRESS:
STREET 1: ONE BOSTON PLACE
STREET 2: 201 WASHINGTON STREET, SUITE 3900
CITY: BOSTON
STATE: MA
ZIP: 02108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vor Biopharma Inc.
CENTRAL INDEX KEY: 0001817229
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 101
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-655-6580
MAIL ADDRESS:
STREET 1: 100 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 101
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
form4-05282024_040508.xml
X0508
4
2024-05-23
0001817229
Vor Biopharma Inc.
VOR
0001690959
Resnick Joshua
C/O VOR BIOPHARMA INC.
100 CAMBRIDGEPARK DRIVE, SUITE 101
CAMBRIDGE
MA
02140
true
false
false
false
0
Stock Option (Right to Buy)
1.61
2024-05-23
4
A
0
30000
0
A
2034-05-22
Common Stock
30000
30000
D
This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 23, 2025 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject
to the Reporting Person's continued service as a director through such date.
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to
the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
/s/ Katie Kazem, Attorney-in-Fact
2024-05-28